Comparison of DuP 996, with physostigmine, THA and 3,4-DAP on hypoxia-induced amnesia in rats.
DuP 996, 3,3-bis(4-pyrindinylmethyl)-1-phenylindolin-2-one, physostigmine (PH), tetrahydroaminoacridine (THA) and 3,4-diaminopyridine (3,4-DAP) were compared for their ability to protect against hypoxia-induced performance deficits in a passive avoidance (PA) task. The ability to retain PA response was found to decrease as the oxygen concentration decreased with the largest retention deficit occurring at 6.5% oxygen. DuP 996 (0.01-0.1 mg/kg SC), 3,4-DAP (0.1-10.0 mg/kg SC), THA (0.3-5.0 mg/kg SC) and PH (0.001-0.1 mg/kg SC) administered one minute after PA training produced dose-dependent increases in retention latencies following exposure to 6.5% oxygen. In comparing each compound for side effects, DuP 996 induced tremor and mortality at 10 and 40 mg/kg SC, respectively, and PH at 0.3 and 0.8 mg/kg SC, respectively. With PH the 0.3 mg/kg SC dose also produced hypersalivation and a decrease in lift strength. THA produced tremor and mortality at 6.0 and 40 mg/kg SC, respectively, and 3,4-DAP at 50 and 200 mg/kg SC, respectively. 3,4-DAP also produced chromodacryorrhea and hypersalivation at 50 mg/kg SC. Dividing the dose necessary to produce mortality by the highest effective dose active in the hypoxia test yielded a safety ratio for DuP 996 of 400, for 3,4-DAP 20, for PH 8, and for THA 8, showing a greater safety margin for DuP 996 than the other cholinergic agents. These results suggest that DuP 996 may be of use in the treatment of diseases associated with cognitive impairment and may have a greater safety margin than other cholinergic agents.
DeNoble
V J
VJ
E. I. du Pont de Nemours & Co., Inc., Medical Products Department, Wilmington, DE 19880-0400.
DeNoble
K F
KF
Spencer
K R
KR
Johnson
L C
LC
Cook
L
L
Myers
M J
MJ
Scribner
R M
RM
D015761:4-Aminopyridine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D000647:Amnesia / Q000209:etiology / Q000517:prevention & control*; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D000860:Hypoxia / Q000150:complications*; D007211:Indoles / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects; D010275:Parasympathetic Nervous System / Q000187:drug effects; D010830:Physostigmine / Q000009:adverse effects / Q000494:pharmacology*; D011725:Pyridines; D051381:Rats; D011919:Rats, Inbred Strains; D013619:Tacrine / Q000009:adverse effects / Q000494:pharmacology*
D007211:Indoles; D011725:Pyridines; D013619:Tacrine; C026805:2,4-diaminopyridine; D010830:Physostigmine; D015761:4-Aminopyridine; C061017:linopirdine